Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) PT at $43.38

Maze Therapeutics, Inc. (NASDAQ:MAZE) has earned an average recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $43.3750.

Several equities analysts have recently issued reports on MAZE shares. HC Wainwright upped their price objective on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, December 3rd. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 price target on the stock. JPMorgan Chase & Co. upped their target price on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Wedbush boosted their price target on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, Guggenheim restated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a research note on Friday, December 19th.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analysts have been raising ratings and targets (consensus remains a “Buy”, average PT ? $43.38), supporting upside expectations. Analyst Ratings/Targets
• Positive Sentiment: Several institutions have increased or initiated stakes (e.g., Vanguard, Frazier, ARCH, Marshall Wace), indicating institutional interest that can underpin the stock. Institutional Ownership Details
• Neutral Sentiment: Recent Q3/Q4 results showed an EPS beat (reported -$0.66 vs. -$0.74 consensus), which is supportive but the company remains unprofitable and clinical-stage. Earnings Summary
• Neutral Sentiment: A de?minimis sale of 100 shares by insider Atul Dandekar (Dec. 30) is immaterial on its own. Small Form 4
• Negative Sentiment: Atul Dandekar sold 72,400 shares (~$2.94M at ~$40.56) and reduced his stake by ~87.3% — the largest and most sentiment?negative transaction reported. Dandekar Form 4
• Negative Sentiment: CMO Harold Bernstein sold 45,000 shares (~$1.83M at ~$40.56). Large C?suite sales can raise questions on insider conviction and add selling pressure. Bernstein Form 4
• Negative Sentiment: SVP Amy Bachrodt sold a total of 15,000 shares across Dec. 29–30 (~$606K combined; sales at ~$40.58 and ~$40.08), materially reducing her stake. Multiple insider sales may weigh on near?term sentiment. Bachrodt Form 4

Maze Therapeutics Trading Up 3.4%

NASDAQ MAZE opened at $41.43 on Tuesday. The firm’s fifty day simple moving average is $36.81 and its two-hundred day simple moving average is $24.70. The firm has a market capitalization of $1.99 billion and a P/E ratio of -1.98. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $43.29.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.08.

Insider Activity

In other Maze Therapeutics news, CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares in the company, valued at $426,001.68. This represents a 87.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 132,500 shares of company stock valued at $5,371,980 in the last ninety days.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently modified their holdings of MAZE. Invesco Ltd. acquired a new position in shares of Maze Therapeutics in the first quarter worth about $226,000. Goldman Sachs Group Inc. acquired a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $145,000. Ensign Peak Advisors Inc purchased a new position in shares of Maze Therapeutics in the 2nd quarter valued at about $227,000. Frazier Life Sciences Management L.P. raised its holdings in Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares during the period. Finally, Nuveen LLC purchased a new position in Maze Therapeutics during the first quarter worth approximately $125,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.